Objective: We aimed to assess adalimumab(ADA) and infliximab(IFX) efficacy on the patients of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) by using erithrocyte sedimentation rate (ESR), C-reactive protein (CRP), interferon gamma (IF-?), interleukin-1 beta (IL-1ß), interleukin 6 (IL- 6), matrix metalloproteinase 3 (MMP-3).
Material and Method: Sixteen RA, 15 AS patients were enrolled to this study. ADA was used on the half of RA patients , IFX was used on the other half randomly. ADA was used on 7 AS patients and IFX was used on 8 AS patients randomly too. Blood samples were taken at the weeks of 0, 1, 4 and 12. ESR and CRP were calculated at the same time with controls. Blood samples were hidden at the -20°C to evaluate after.
Results: There wasnt any significant difference between the groups of RA and AS patients in terms of ESH and CRP levels (p>0.05). IF-? was found lower on both patient groups and IL-6 and IL-1ß were not included statistical analysis due to the wide range of values. MMP-3 levels was found correlated with ESR and CRP levels in both treatment and patient groups. MMP -3 was more supressed at ADA treated group on AS patients according to the IFX group on AS patients significantly (p
Key words: Rheumatoid arthritis, ankylosing spondylitis, adalimmumab, infliximab
|
